Kristi Rosa

Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.

Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.

Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.

Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

Phase 1/2 data highlight the benefit of linvoseltamab even among prespecified high-risk patient subgroups with relapsed/refractory multiple myeloma.

Data from STARGLO showed that fixed-duration glofitamab-gxbm (Columvi) plus gemcitabine/oxaliplatin significantly improved survival compared with rituximab (Rituxan) plus gemcitabine/oxaliplatin in select patients with relapsed/refractory diffuse large B-cell lymphoma.

Blinatumomab demonstrated “impressive activity” in the ALLTogether1 DS study, according to Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD.

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

The CheckMate 816 trial reinforced the EFS data of nivolumab plus chemotherapy in resectable NSCLC.

A trend towards improved progression-free survival was not noted when pembrolizumab plus sacituzumab govitecan was used to treat patients with HR+ breast cancer.

Data from the ADRIATIC trial show consistent PFS and OS benefits with durvalumab across predefined limited-stage small cell lung cancer subgroups.

Increased PFS was noted with abemaciclib plus fulvestrant vs fulvestrant alone in hormone receptor–positive, HER2-negative advanced breast cancer after disease progression on a CDK4/6 inhibitor and endocrine therapy.

A reduction in splenomegaly was observed when the combination of pelabresib plus ruxolitinib was used to treat patients with myelofibrosis.

Ponatinib remains a safe treatment for patients with chronic-phase chronic myeloid leukemia.

Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.

A 50% objective response rate was observed when becotarug plus osimertinnib was combined to treat patients with EGFR exon 12 non–small cell lung cancer.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Findings from the phase 1/2 TRANSCEND CLL 004 trial support lisocabtagene maraleucel as a potential new treatment option for relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Combining pembrolizumab with cabozantinib produces encouraging efficacy in platinum-ineligible patients with advanced urothelial carcinoma, says Rohit K. Jain, MD, MPH.

Investigators observe a benefit with durvalumab plus neoadjuvant chemotherapy among subgroups of patients regardless of microsatellite instability status in the phase 3 MATTERHORN trial.

Treatment with anito-cel produces deep, enduring responses in high-risk relapsed/refractory multiple myeloma, says Matthew Frigault, MD.

Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.

Data from the phase 1/2 BRUIN study support continuous BTK pathway inhibition as an important sequencing approach in chronic lymphocytic leukemia or small lymphocytic lymphoma, says Jennifer A. Woyach, MD.

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

The pembrolizumab-based regimen in the phase 3 KEYNOTE-756 trial produces a larger pathologic complete response benefit in patients with node-positive disease and higher PD-L1 expression, according to Joyce O’Shaughnessy, MD.

Patients with RET fusion–positive non–small cell lung cancer experienced improved progression-free survival with first-line selpercatinib.

Results from the phase 2 PERLA trial showed an improved objective response and overall survival in treatment with dostarlimab plus chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Findings from the phase 3 AEGEAN trial suggest that patients with EGFR-mutated non–small cell lung cancer experience similar outcomes whether receiving durvalumab or placebo.

Iruplinalib appears tolerable with no new safety signals among patients with locally advanced and metastatic ALK-positive non–small cell lung cancer in the phase 3 INSPIRE trial.